Data as of May 22
| -0.41 / -1.08%|
Forest Laboratories, Inc. develops, manufactures and sells branded forms of ethical drug products, which require a physician's prescription. The company offers a range of prescription products, under the brand names Bystolic, a beta-1 selective beta-blocker with vasodilating properties; Daliresp, a orally administered and selective phosphodiesterase 4 enzyme inhibitor, a treatment to reduce the risk of exacerbations in patients with severe chronic obstructive pulmonary disease associated with chronic bronchitis and a history of exacerbations; Lexapro, a single isomer version of citalopram HBr, for the treatment of MDD in adults and adolescents and generalized anxiety disorder in adults; Namenda, a moderate affinity, uncompetitive N-methyl-D-Aspartate receptor agonist for the treatment of moderate and severe Alzheimer's disease; Savella, a serotonin and norepinephrine reuptake inhibitor for the management of fibromyalgia; Teflaro for the treatment of adults with community-acquired bacterial pneumonia, including cases caused by Streptococcus pneumoniae bacteremia and with acute bacterial skin and skin structure infections, including cases caused by methicillin resistant Staphylococcus aureus, and Viibryd, an antidepressant developed by clinical data for the treatment of adults with major depressive disorders. Forest Laboratories was founded in 1954 and is headquartered in New York, NY.
|Howard Solomon||Chairman, President & Chief Executive Officer|
|Kevin Walsh||Senior Vice President & Operations Director|
|Francis I. Perier, Jr.||Chief Financial Officer & EVP-Administration|
|Marco Taglietti, MD||Senior Vice President-Research & Development|
|Elaine Hochberg||Chief Commercial Officer & Executive VP|